Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer; NHGRI; 3M; and More

NEW YORK (GenomeWeb) – PerkinElmer this week declared a regular quarterly dividend of $.07 per share of common stock. This dividend is payable on Aug. 10 to all shareholders of record at the close of business on July 15.

The National Human Genome Research Institute announced this week that it has created the Atlas of Human Malformation Syndromes in Diverse Populations. The atlas is intended to help health care providers diagnose diverse patients with inherited diseases by comparing phenotypes and written descriptions of their symptoms with photos and descriptions of people with the same condition and ancestry, NHGRI said. The agency has added Down syndrome and 22q11.2 deletion syndrome to the atlas first.

3M announced this week that its 3M Molecular Detection Assay 2 – Salmonella has been approved as an official method of analysis by the independent association AOAC International. The validation certifies that the test kit is equivalent or better at detecting salmonella in food and the environment than standard reference methods, the company said. The salmonella assay is part of the 3M Molecular Detection System pathogen testing platform.

The HudsonAlpha Foundation said this week it has established the Memory and Mobility Fund for neurological disease research. The fund will support neurological disease research being conducted at the HudsonAlpha Institute for Biotechnology. The first project will be to sequence the genomes of 1,500 patients with Alzheimer’s disease and Alzheimer-related dementia, the foundation said.

DNA2.0 announced this week that it has agreed to purchase all assets of MIGS, a contract research company specializing in the production of antibody and antibody-like molecules that support preclinical studies with microgram to gram quantities of protein. MIGS Founder Michael Feldhaus will join DNA2.0 as senior vice president of antibody technologies. Financial terms of the deal were not disclosed.

GenoVive this week signed a partnership agreement with FitLab, a division of Unilab Consumer Health, to offer its personalized health program in Southeast Asia. GenoVive designs diet and fitness regimens for individuals based on their genome.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.